SCHEDULE: Vanguard Discloses 8.94% Stake in ADMA Biologics

The Vanguard Group has reported a significant beneficial ownership stake of 8.94% in ADMA Biologics Inc., totaling over 21 million shares.

Summary

• The Vanguard Group, an investment adviser, has filed an Amendment No. 3 to Schedule 13G, disclosing its beneficial ownership in ADMA Biologics Inc.
• As of June 30, 2025, Vanguard beneficially owns 21,363,715 shares of ADMA Biologics' Common Stock.
• This ownership represents 8.94% of the class of securities.
• Vanguard holds sole voting power over 0 shares and shared voting power over 297,618 shares.
• Vanguard holds sole dispositive power over 20,770,642 shares and shared dispositive power over 593,073 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in sentiment. The presence of a large institutional investor can be seen as a positive signal, but the filing itself does not contain performance or operational updates.

Positives

• The disclosure of a significant stake by a major institutional investor like The Vanguard Group can be perceived as a vote of confidence in ADMA Biologics Inc.
• Vanguard's certification states that the shares are not held for the purpose of changing or influencing control of the issuer, indicating a passive investment approach.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from ADMA Biologics Inc. or The Vanguard Group regarding the issuer's future performance.

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of ADMA Biologics Inc.

Industry Context

Large institutional holdings, such as the one disclosed by Vanguard, are common across publicly traded companies and reflect the investment strategies of major fund managers to gain exposure to various sectors and companies. This filing indicates Vanguard's continued or updated passive investment in the biotechnology sector through ADMA Biologics.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake can influence investor perception and potentially market liquidity for ADMA Biologics' stock.

Key Dates

Keywords

ADMA Biologics, Vanguard Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Investment Adviser